Skip to main content

Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma

International Journal of Hematology volume 110, pages 69–76 (2019)Cite this article

Abstract

Monoclonal antibodies against surface antigens on MM cells, such as anti-SLAMF7 and anti-CD38 antibodies, represent an attractive therapeutic modality for the eradication of multiple myeloma (MM) cells. However, further exploration of target molecules is urgently needed for the development of more effective therapies. In the present study, we studied the expression of CD48 in a total of 74 primary MM samples derived from patients to evaluate SLAMF2 (CD48) as a candidate in mAb therapy for MM. Of 74 samples, 39 were subjected to SLAMF7 analysis. Most of the MM cells, defined as CD38 and CD138 double-positive cells, showed strong expression of CD48 or SLAMF7 independent of disease stage or treatment history. In these 39 samples, most MM cells showed expression of both SLAMF7 and CD48; however, several samples showed expression of either only CD48 or only SLAMF7, including seven cases that were only highly positive for SLAMF7, and five that were only highly positive for CD48. Our study demonstrates that the immune receptor CD48 is overexpressed on MM cells together with SLAMF7, and that CD48 may be considered as an alternative target for treatment of MM in cases showing weak expression of SLAMF7.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. Palumbo A, Mina R. Management of older adults with multiple myeloma. Blood Rev. 2013;27:133–42.

    Article  CAS  PubMed  Google Scholar 

  2. Wang TF, Ahluwalia R, Fiala MA, Trinkaus KM, Cox DP, Jaenicke M, et al. The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide. Leuk Lymphoma. 2014;55:337–41.

    Article  CAS  PubMed  Google Scholar 

  3. Tai YT, Li X, Tong X, Santos D, Otsuki T, Catley L, et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005;65:5898–906.

    Article  CAS  PubMed  Google Scholar 

  4. Phipps C, Chen Y, Gopalakrishnan S, Tan D. Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development. Ther Adv Hematol. 2015;6:120–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 2011;96:284–90.

    Article  CAS  PubMed  Google Scholar 

  6. Sondergeld P, van de Donk NW, Richardson PG, Plesner T. Monoclonal antibodies in myeloma. Clin Adv Hematol Oncol. 2015;13:599–609.

    PubMed  Google Scholar 

  7. Yang J, Qian J, Wezeman M, Wang S, Lin P, Wang M, et al. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell. 2006;10:295–307.

    Article  CAS  PubMed  Google Scholar 

  8. Hadari Y, Schlessinger J. FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma. J Clin Investig. 2009;119:1077–9.

    Article  CAS  PubMed  Google Scholar 

  9. Hosen N, Ichihara H, Mugitani A, Aoyama Y, Fukuda Y, Kishida S, et al. CD48 as a novel molecular target for antibody therapy in multiple myeloma. Br J Haematol. 2012;156:213–24.

    Article  CAS  PubMed  Google Scholar 

  10. Muccio VE, Saraci E, Gilestro M, Gattei V, Zucchetto A, Astolfi M, et al. Multiple myeloma: new surface antigens for the characterization of plasma cells in the era of novel agents. Cytom Part B Clin Cytom. 2016;90:81–90.

    Article  CAS  Google Scholar 

  11. Calpe S, Wang N, Romero X, Berger SB, Lanyi A, Engel P, et al. The SLAM and SAP gene families control innate and adaptive immune responses. Adv Immunol. 2008;97:177–250.

    Article  CAS  PubMed  Google Scholar 

  12. Cannons JL, Tangye SG, Schwartzberg PL. SLAM family receptors and SAP adaptors in immunity. Annu Rev Immunol. 2011;29:665–705.

    Article  CAS  PubMed  Google Scholar 

  13. Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62:1841–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Wang N, Morra M, Wu C, Gullo C, Howie D, Coyle T, et al. CD150 is a member of a family of genes that encode glycoproteins on the surface of hematopoietic cells. Immunogenetics. 2001;53:382–94.

    Article  CAS  PubMed  Google Scholar 

  15. Boles KS, Stepp SE, Bennett M, Kumar V, Mathew PA. 2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes. Immunol Rev. 2001;181:234–49.

    Article  CAS  PubMed  Google Scholar 

  16. Thorley-Lawson DA, Poodry CA. Identification and isolation of the main component (gp350-gp220) of Epstein–Barr virus responsible for generating neutralizing antibodies in vivo. Immunol Rev. 2001;181:234–49.

    Article  Google Scholar 

  17. Sun H, Biggs JC, Smith GM. Antitumour activity of a chimeric antibody against the leucocyte antigen CD48. Cancer Immunol Immunother. 2000;48:595–602.

    Article  CAS  PubMed  Google Scholar 

  18. Greenaway S, Henniker AJ, Walsh M, Bradstock KF. A pilot clinical trial of two murine monoclonal antibodies fixing human complement in patients with chronic lymphatic leukaemia. Leuk Lymphoma. 1994;13:323–31.

    Article  CAS  PubMed  Google Scholar 

  19. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.

    Article  PubMed  Google Scholar 

  20. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Inagaki A, Tajima E, Uranishi M, Totani H, Asao Y, Ogura H, et al. Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma. Leuk Res. 2013;37:1648–55.

    Article  CAS  PubMed  Google Scholar 

  22. Narita T, Ri M, Masaki A, Mori F, Ito A, Kusumoto S, et al. Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy. Blood Cancer J. 2015;5:e373.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018;124:4032–43.

    Article  CAS  PubMed  Google Scholar 

  24. Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018;103:2088–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018;103:2079–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Lewis TS, Olson D, Gordon K, Sandall S, Quick M, Finn M, et al. SGN-CD48A: a novel humanized anti-CD48 antibody-drug conjugate for the treatment of multiple myeloma. Blood. 2016;128:4470.

    Google Scholar 

Download references

Acknowledgements

We thank Ms. Chiori Fukuyama for her skillful technical assistance. The study received financial support from Bristol-Myers Squibb. We acknowledge the support of the Egyptian Ministry of Higher Education (Cultural Affairs Sector and Missions). This work was partly supported by a Grant-in-Aids for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology (16K07179 & 16K09855), the National Cancer Center Research and Development Fund (26-A-4), and the Practical Research for Innovative Cancer Control from the Japan Agency for Medical Research and Development, AMED (15ck0106077h0002).

Author information

Affiliations

  1. Division of Blood Transfusion, Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan

    Reham Ashour, Masaki Ri, Takashi Yoshida, Takuto Tachita, Takashi Kanamori, Sho Aoki, Shiori Kinoshita, Tomoko Narita, Haruhito Totani, Ayako Masaki, Asahi Ito, Shigeru Kusumoto, Hirokazu Komatsu & Shinsuke Iida

  2. Department of Clinical Pathology, Qena University Hospital, South Valley University, Qena, Egypt

    Reham Ashour, Sanaa Shaker Aly & Abdelrahman A. Elsaied

  3. Division of Blood Transfusion, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

    Masaki Ri

  4. Clinical Pathology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt

    Samar Mansour

  5. Department of Gastroenterology and Hematology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan

    Takuto Tachita

Authors
  1. Reham Ashour
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masaki Ri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sanaa Shaker Aly
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takashi Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takuto Tachita
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takashi Kanamori
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sho Aoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shiori Kinoshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tomoko Narita
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Haruhito Totani
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ayako Masaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Asahi Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Shigeru Kusumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hirokazu Komatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Samar Mansour
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Abdelrahman A. Elsaied
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Shinsuke Iida
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masaki Ri.

Ethics declarations

Conflict of interest

MR received research funding from Celgene Co., Ltd. SI received research funding and declares Honoraria from Janssen Pharmaceutical K.K., and Celgene Co., Ltd. SI also received research funding from Kyowa Hakko Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd, Bristol-Myers Squibb, Takeda Yakuhin Co., Ltd., and Ono Pharmaceutical CO., Ltd.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 122 kb)

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ashour, R., Ri, M., Aly, S.S. et al. Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma. Int J Hematol 110, 69–76 (2019). https://doi.org/10.1007/s12185-019-02649-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-019-02649-3

Keywords

  • CD48
  • SLAMF
  • Multiple myeloma
  • Flow cytometry